fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Caspofungin

All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules

Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysNot paid by ODB 65 and over without Exceptional Access approval; this DIN is on the ministry's EAP drug list: submit an EAP request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry

Cancidas · DIN 02244266 · 70 mg/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Cancidas · DIN 02244266 Manufacturer: Merck Frosst Canada & Cie, Merck Frosst Canada & Co.; listing date 2017-08-30 Health Canada: Marketed since 2006-07-05 · brand CANCIDAS · ATC J02AX04 CASPOFUNGIN · form Powder for solution · route Intravenous · ingredients CASPOFUNGIN (CASPOFUNGIN ACETATE) 70 MG/VIAL · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Cancidas: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02244266)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02244266). DIN 02244266: Cancidas Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 920000530; group id 903; item number 2163; lccId None; manufacturer id FRS Source form: Inj Pd-Vial Pk; strength: 70mg/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244266 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68233
Interchangeable products
Caspofungin for Injection · DIN 02460955 · $222.0000 Caspofungin for Injection · DIN 02486997 · $222.5000
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244266
Shortage record checked October 6, 2026

Caspofungin for Injection · DIN 02460955 · 70 mg/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
Caspofungin for Injection · DIN 02460955 Manufacturer: Juno Pharmaceuticals Corp.; listing date 2017-08-30 Health Canada: Marketed since 2026-04-27 · brand CASPOFUNGIN FOR INJECTION · ATC J02AX04 CASPOFUNGIN · form Powder for solution · route Intravenous · ingredients CASPOFUNGIN (CASPOFUNGIN ACETATE) 70 MG/VIAL · company Juno pharma canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Caspofungin for Injection: Formulary list price $222.00 per unit (the source does not state the unit; exact figure $222.0000). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02460955)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02460955). DIN 02460955: Caspofungin for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 920000530; group id 903; item number 2163; lccId None; manufacturer id JUN Source form: Inj Pd-Vial Pk; strength: 70mg/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $222.0000; ministry $222.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02460955 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94847
Interchangeable products
Cancidas · DIN 02244266 · not recorded Caspofungin for Injection · DIN 02486997 · $222.5000
Shortage status: resolved shortage (ended August 6, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02460955
Shortage record checked October 6, 2026

Caspofungin for Injection · DIN 02486997 · 70 mg/Vial · powder for injection, vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
Caspofungin for Injection · DIN 02486997 Manufacturer: Fresenius Kabi Canada Ltd.; listing date 2020-05-29 Health Canada: Marketed since 2020-01-27 · brand CASPOFUNGIN FOR INJECTION · ATC J02AX04 CASPOFUNGIN · form Powder for solution · route Intravenous · ingredients CASPOFUNGIN (CASPOFUNGIN ACETATE) 70 MG/VIAL · company Fresenius kabi canada ltd · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Caspofungin for Injection: Formulary list price $222.50 per unit (the source does not state the unit; exact figure $222.5000). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02486997)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02486997). DIN 02486997: Caspofungin for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 920000530; group id 903; item number 2163; lccId None; manufacturer id FKC Source form: Inj Pd-Vial Pk; strength: 70mg/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $222.5000; ministry $222.5000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02486997 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97714
Interchangeable products
Cancidas · DIN 02244266 · not recorded Caspofungin for Injection · DIN 02460955 · $222.0000
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02486997
Shortage record checked October 6, 2026

Other products in the same Health Canada class (J02A, J02AX): coverage varies; not interchangeable

  • Micafungin (Mycamine): not a benefit
  • Amphotericin b (Fungizone): general benefit
  • Fluconazole (Diflucan P.O.S.): general benefit, limited Use 528, not a benefit
  • Itraconazole (Sporanox): general benefit, limited Use 570, not a benefit
  • Ketoconazole (Nizoral): general benefit, not a benefit
  • Voriconazole (Vfend): limited Use 399

1 more in the class list below

Caspofungin acetate

All injection strengths: not a benefit

Caspofungin for Injection · DIN 02460947 · 50 mg/Vial · injection-vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot paid by ODB 65 and over without Exceptional Access approval; this DIN is on the ministry's EAP drug list: submit an EAP request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
Caspofungin for Injection · DIN 02460947 Manufacturer: Juno Pharmaceuticals Corp.; listing date 2017-08-30 Health Canada: Marketed since 2026-04-27 · brand CASPOFUNGIN FOR INJECTION · ATC J02AX04 CASPOFUNGIN · form Powder for solution · route Intravenous · ingredients CASPOFUNGIN (CASPOFUNGIN ACETATE) 50 MG/VIAL · company Juno pharma canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Caspofungin for Injection: Formulary list price $222.00 per unit (the source does not state the unit; exact figure $222.0000). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02460947)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02460947). DIN 02460947: Caspofungin for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081204027; group id 7; item number 0009; lccId None; manufacturer id JUN Source form: Inj-Vial Pk; strength: 50mg/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $222.0000; ministry $222.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02460947 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94846
Interchangeable products
Cancidas · DIN 02244265 · not recorded Caspofungin for Injection · DIN 02486989 · $222.5000
Shortage status: resolved shortage (ended August 6, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02460947
Shortage record checked October 6, 2026

Caspofungin for Injection · DIN 02486989 · 50 mg/Vial · injection-vial

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot paid by ODB 65 and over without Exceptional Access approval; this DIN is on the ministry's EAP drug list: submit an EAP request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
Caspofungin for Injection · DIN 02486989 Manufacturer: Fresenius Kabi Canada Ltd.; listing date 2020-05-29 Health Canada: Marketed since 2020-01-27 · brand CASPOFUNGIN FOR INJECTION · ATC J02AX04 CASPOFUNGIN · form Powder for solution · route Intravenous · ingredients CASPOFUNGIN (CASPOFUNGIN ACETATE) 50 MG/VIAL · company Fresenius kabi canada ltd · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Caspofungin for Injection: Formulary list price $222.50 per unit (the source does not state the unit; exact figure $222.5000). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02486989)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02486989). DIN 02486989: Caspofungin for Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081204027; group id 7; item number 0009; lccId None; manufacturer id FKC Source form: Inj-Vial Pk; strength: 50mg/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $222.5000; ministry $222.5000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02486989 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97713
Interchangeable products
Cancidas · DIN 02244265 · not recorded Caspofungin for Injection · DIN 02460947 · $222.0000
Shortage status: anticipated shortage (last updated October 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02486989
Shortage record checked October 6, 2026

Cancidas · DIN 02244265 · 50 mg/Vial · injection-vial

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2026-04-14 — choose a marketed DIN from the same-category list.Discontinued April 14, 2026 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2026-04-14 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2026-04-14 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over without Exceptional Access approval; this DIN is on the ministry's EAP drug list: submit an EAP request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Cancidas · DIN 02244265 Manufacturer: Merck Frosst Canada & Cie, Merck Frosst Canada & Co.; listing date 2017-08-30 Health Canada: Cancelled post market since 2026-04-14 · brand CANCIDAS · ATC J02AX04 CASPOFUNGIN · form Powder for solution · route Intravenous · ingredients CASPOFUNGIN (CASPOFUNGIN ACETATE) 50 MG/VIAL · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Cancidas: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02244265)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02244265). DIN 02244265: Cancidas Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081204027; group id 7; item number 0009; lccId None; manufacturer id FRS Source form: Inj-Vial Pk; strength: 50mg/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244265 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68232
Interchangeable products
Caspofungin for Injection · DIN 02460947 · $222.0000 Caspofungin for Injection · DIN 02486989 · $222.5000
Shortage status: discontinued (April 14, 2026, reported by MERCK CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244265
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since April 14, 2026 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (J02A, J02AX): coverage varies; not interchangeable

  • Micafungin (Mycamine): not a benefit
  • Amphotericin b (Fungizone): general benefit
  • Fluconazole (Diflucan P.O.S.): general benefit, limited Use 528, not a benefit
  • Itraconazole (Sporanox): general benefit, limited Use 570, not a benefit
  • Ketoconazole (Nizoral): general benefit, not a benefit
  • Voriconazole (Vfend): limited Use 399

1 more in the class list below

Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (08:12:04 Antifungals) and how they are covered

Matched class: 08:12:04 Antifungals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: AMPHOTERICIN B Some products covered without a code (check the product listing): FLUCONAZOLE, ITRACONAZOLE, KETOCONAZOLE, NYSTATIN, TERBINAFINE HCL 08:12:04 Antifungals

MICAFUNGIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial, 100mg/Vial · Inj Pd-10mL Vial Pk

AMPHOTERICIN B

· 1 products · General benefit · strengths: · Inj Pd-50mg Pk

FLUCONAZOLE

· 17 products · Limited Use, codes 528 (1), Listed, not a benefit (2), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (12) · strengths: 10mg/mL, 50mg, 100mg · O/L, Tab

ITRACONAZOLE

· 5 products · General benefit (2), Listed, not a benefit (1), Limited Use, codes 570 (2) · strengths: 100mg, 10mg/mL · Cap, Oral Sol

KETOCONAZOLE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 200mg · Tab

VORICONAZOLE

· 6 products · Limited Use, codes 399 · strengths: 50mg, 200mg · Tab

POSACONAZOLE

· 7 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 40mg/mL · DR Tab, O/L

NYSTATIN

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 100000U/mL · O/L

TERBINAFINE HCL

· 8 products · Listed, not a benefit (1), General benefit (7) · strengths: 250mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:04
Full class listing Related classes: 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles

Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

GLUCAGON RDNA ORIGIN

· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk

LANREOTIDE ACETATE

· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE CANCIDAS® is indicated for use in adults and children 12 months and older for:  Empirical therapy for presumed fungal infections in febrile, neutropenic patients (see CLINICAL TRIALS).  Treatment of Invasive Candidiasis including candidemia, intra-abdominal abscesses, peritonitis and pleural space infections. CANCIDAS® has not been studied in Candida endocarditis, osteomyelitis or meningitis (see CLINICAL TRIALS).  Treatment of Esophageal Candidiasis (see CLINICAL TRIALS).  Treatment of Invasive Aspergillosis in patients who are refractory to or intolerant of other therapies. The indication is based on results from an open-label, non-comparative study that enrolled 69 adult patients with documented invasive aspergillosis refractory to or intolerant of other therapies. CANCIDAS® has not been studied as initial therapy for invasive aspergillosis (see CLINICAL TRIALS). CANCIDAS® (caspofungin acetate) Page 3 of 50 Geriatrics (≥ 65 years of age): In a limited number of patients  65 years of age, no overall differences in safety or efficacy have been obs… https://pdf.hres.ca/dpd_pm/00039081.PDF PM date: April 28, 2017 Source product: CANCIDAS; DIN 02244266; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Caspofungin for Injection is indicated for use in adults and children 12 months and older for: • Empirical therapy for presumed fungal infections in febrile, neutropenic patients (see CLINICAL TRIALS). • Treatment of Invasive Candidiasis including candidemia, intra-abdominal abscesses, peritonitis and pleural space infections. Caspofungin acetate has not been studied in Candida endocarditis, osteomyelitis or meningitis (see CLINICAL TRIALS). • Treatment of Esophageal Candidiasis (see CLINICAL TRIALS). • Treatment of Invasive Aspergillosis in patients who are refractory to or intolerant of other therapies. The indication is based on results from an open-label, non-comparative study that enrolled 69 adult patients with documented invasive aspergillosis refractory to or intolerant of other therapies. Caspofungin acetate has not been studied as initial therapy for invasive aspergillosis (see CLINICAL TRIALS). Caspofungin for Injection Page 3 of 50 Geriatrics (≥ 65 years of age): In a limited number of patients  65 years of age, no overa… https://pdf.hres.ca/dpd_pm/00084449.PDF PM date: APR 27, 2026 Source product: CASPOFUNGIN FOR INJECTION; DIN 02460947; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Cancidas · DIN 02244266 Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244266

Check this DIN again

Caspofungin for Injection · DIN 02486997 Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02486997

Check this DIN again

Cancidas · DIN 02244265 Shortage status: discontinued (2026-04-14, reported by MERCK CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244265

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Cancidas, Caspofungin for Injection: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026